Skip to main content

18-09-2019 | Diabetes | News | Article

EASD 2019

Semaglutide tops liraglutide in SUSTAIN 10

medwireNews: Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs (OADs) in people with type 2 diabetes.

Presenting the results at the 55th EASD Annual Meeting in Barcelona, Spain, Matthew Capehorn (Rotherham Institute for Obesity, UK) explained that 577 adults receiving 1–3 OADs were randomly assigned to receive open-label add-on treatment with once weekly subcutaneous semaglutide 1.0 mg or once daily subcutaneous liraglutide 1.2 mg. These doses were “expected to reflect clinical practice” in Europe, he said.

Capehorn reported that average glycated hemoglobin (HbA1c) levels decreased by 1.7% from baseline to week 30 among the 290 individuals in the semaglutide group, compared with 1.0% among the 287 participants given liraglutide, a significant difference. Mean HbA1c levels at baseline were 8.2% and 8.3% in the semaglutide and liraglutide groups, respectively.

Patients given semaglutide also experienced a significantly greater weight loss on average than those given liraglutide (5.8 vs 1.9 kg).

Capehorn added that the glucagon-like peptide-1 receptor agonists had similar overall safety profiles in the SUSTAIN 10 trial, with 70.6% and 66.2% of people in the semaglutide and liraglutide groups, respectively, experiencing adverse events. Rates of gastrointestinal adverse events were higher in the semaglutide than the liraglutide arm (43.9 vs 38.3%).

The SUSTAIN 10 results were published simultaneously in Diabetes & Metabolism.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

EASD 2019; Barcelona, Spain: 16–20 September
Diabetes Metab 2019; doi:10.1016/j.diabet.2019.101117